Table 2.
Performances of diagnostic tests with 158 specimens of BAL fluid
| Parameter for proven and probable IA vs no IAa | Test result (95% CI) [no. of specimens with result/no. tested] by: |
|||
|---|---|---|---|---|
| MycAssay Aspergillus PCR | In-house Aspergillus PCR | GM ELISA |
||
| Index cutoff, ≥1.0 | Index cutoff, ≥0.5 | |||
| Sensitivity (%) | 94.1 (71-99) [16/17] | 88.2 (63-98) [15/17] | 94.1 (71-99) [16/17] | 94.1 (71-99) [16/17] |
| Specificity (%) | 98.6 (94-99) [139/141] | 97.9 (93-99) [138/141] | 97.9 (93-99) [138/141] | 92.2 (86-96) [130/141] |
| Likelihood ratiob | ||||
| Positive | 67.2 | 42.0 | 44.8 | 12.1 |
| Negative | 0.06 | 0.12 | 0.06 | 0.06 |
| PPV (%) | 88.9 (65-98) [16/18] | 83.3 (58-96) [15/18] | 84.2 (60-96) [16/19] | 59.3 (38-77) [16/27] |
| NPV (%) | 99.3 (96-99) [139/140] | 98.6 (94-99) [138/140] | 99.3 (96-99) [138/139] | 99.3 (95-99) [130/131] |
| DORc | 1120.0 | 350.0 | 746.6 | 201.6 |
a
Of 158 patients studied, 17 were diagnosed with proven or probable IA according to the revised European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria from 2002 (10).
b
Likelihood ratio positive, sensitivity/1 − specificity; likelihood ratio negative, 1 − sensitivity/specificity.
c
DOR, diagnostic odds ratio (likelihood ratio positive/likelihood ratio negative).